Draco Healthcare Consulting LLC, Feb 2009, Pages: 107
are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan
BioPharm Reports (VennBio Ltd.), June 2010, Pages: 225
, affecting 1 in 3 adults over the age of 20 (Lancet. 2005;365:217-223). Hypertension is commonly seen in developing as well as developed countries and, where it remains untreated, presents a major risk factor
GlobalData, May 2011, Pages: 16
your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies by understanding the trends and developments that are driving or are expected to drive
AMID Co., April 2009, Pages: 188
trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003 and 2008
BioPharm Reports (VennBio Ltd.), Nov 2009, Pages: 225
, affecting 1 in 3 adults over the age of 20 (Lancet. 2005;365:217-223). Hypertension is commonly seen in developing as well as developed countries and, where it remains untreated, presents a major risk factor
John Wiley and Sons Ltd, July 2007, Pages: 276
, Contemporary Drug Synthesis, but with all new therapeutic categories and drugs discussed.
About the Authors:
Douglas S. Johnson, PHD, is a Research Chemist at Pfizer Global Research and Development.
Jie Jack
John Wiley and Sons Ltd, Jan 2011, Pages: 520
This book is a compilation of summarized analytical methods designed to serve the needs of pharmacologists, toxicologists, and other allied health professionals involved the development, use
Business Monitor International, Sep 2009, Pages: 100
) and Micardis (telmisartan).
Although the operating environment for foreign companies remains challenging – with medical devices specialist B Braun Medical Industries mulling the relocation of its manufacturing
Lead Discovery, Oct 2002
leading causes of disability in the US and other developed countries, affecting 9.5% and 15% of the US population respectively. Antidepressants, which are also used for the treatment of anxiety, are largely
